Cambridge personalised medicines pioneer Horizon Diagnostics (HDx) has taken its technology to Japan.
A division of UK business Horizon Discovery, HDx has signed a distribution agreement with RIKEN GENESIS, to become sole distributor of HDx’s molecular reference standards in Japan.
RIKEN GENESIS offers cutting-edge genomic products and services to a wide range of research institutions and corporations and is a CAP (College of American Pathologists) accredited laboratory for genome analysis services.
Reliable and renewable sources of reference standards are essential for molecular laboratories – but a lack of availability has previously been a major obstacle. Even when patient samples are available, variability in DNA extraction and a lack of standardisation have proved to be additional serious sources of error.
Horizon’s HDx division has developed reliable and renewable genetically defined and thoroughly validated reference materials, providing an industry standard for the development of and quality control of molecular assays, thereby directly improving their accuracy.
Horizon’s Molecular Reference Standards include FFPE cell line blocks and purified gDNA. In early 2013 HDx launched its first Quantitative Multiplex DNA Reference Standard, intended for researchers assessing multiple biomarkers in a single assay, using platforms such as next generation sequencing (NGS).
“Part of our mission at RIKEN GENESIS is to contribute to translating the results of genetic research into clinical settings,” said Yusuke Tsukahara, President and CEO. “Horizon’s Molecular Reference Standards are a valuable step in the move towards practical implementation of personalised medicine, and we are delighted to be working with such a forward looking company.”
Dr Brian Burke, business development manager, Horizon Diagnostics, added: “At the cutting edge of genome analysis, RIKEN GENESIS is an ideal partner for Horizon.
“We aim to affiliate ourselves with the best, like-minded companies for distribution; those dedicated to customer service, cutting edge science and ultimately better patient care. We look forward to working with the team to develop the molecular reference standards market in Japan.”
Click Here for original source